DNA microarray in search of new drug targets for myasthenia gravis

Tali Feferman, Revital Aricha, Renuka Menon, Miriam C. Souroujon, Sonia Berrih-Aknin, Sara Fuchs

Research output: Chapter in Book/Report/Conference proceedingConference contributionpeer-review


DNA microarray technology was used to identify new potential drug targets for myasthenia gravis (MG), to delineate genes involved in the pathogenesis of the disease and to possibly target their protein products for immunotherapy. In this study we compared the gene expression in lymph node cells (LNC) and muscles of rats with experimental autoimmune MG (EAMG) to those of control, healthy rats. Of the genes that were found to be deregulated in EAMG, we chose to elaborate on two gene systems: (a) The chemokine IFN-γ-inducible protein 10 (IP-10, CXCL10), and its receptor (CXCR3) and (b) phosphodiesterases.

Original languageEnglish
Title of host publicationAutoimmunity, Part C The Mosaic of Autoimmunity
PublisherBlackwell Publishing Inc.
Number of pages7
ISBN (Print)1573316628, 9781573316620
StatePublished - Jun 2007

Publication series

NameAnnals of the New York Academy of Sciences
ISSN (Print)0077-8923
ISSN (Electronic)1749-6632


  • Autoimmunity
  • Chemokines
  • Combined therapy
  • DNA microarray
  • Myasthenia gravis
  • Phosphodiesterase


Dive into the research topics of 'DNA microarray in search of new drug targets for myasthenia gravis'. Together they form a unique fingerprint.

Cite this